 NEW YORK, Aug. 02, 2021 GLOBE NEWSWIRE -- Immunovant, Inc. Nasdaq: IMVT, a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has received a 200 million strategic investment from Roivant Sciences. Immunovant intends to use the proceeds from this investment to advance the development of IMVT-1401 in multiple indications. 